Novartis Heart Drug Doesn't Prove Benefit, FDA Staff Says

Novartis Heart Drug Doesn't Prove Benefit, FDA Staff Says

Novartis relied on one clinical trial instead of two that the FDA prefers, and the benefit serelaxin showed may not be meaningful, according to the clinical review prepared by the FDA's Melanie Blank and Tzu-Yun McDowell. Novartis's main goal in the

9
Like
Save

Comments

Write a comment

*